The most frequently reported grade @ or @ adverse events in the everolimus group versus the placebo group were neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , stomatitis ( @ -LSB- @ % -RSB- vs three -LSB- @ % -RSB- ) , anaemia ( @ -LSB- @ % -RSB- vs six -LSB- @ % -RSB- ) and diarrhoea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) On-treatment adverse event-related deaths were reported in @ ( @ % ) patients in the everolimus group and none in the placebo group .